問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Psychiatry

更新時間:2023-09-19

陳牧宏Chen, Mu-Hong
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

篩選

List

13Cases

2025-10-15 - 2031-11-14

Phase III

Not yet recruiting
A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants with Acute Suicidal Ideation or Behavior
  • Condition/Disease

    Major Depressive Disorder in Adolescent Participants with Acute Suicidal Ideation or Behavior

  • Test Drug

    nasal spray

Participate Sites
5Sites

Recruiting5Sites

2018-03-01 - 2021-03-31

Phase III

Completed
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation
  • Condition/Disease

    Schizophrenia

  • Test Drug

    Paliperidone Palmitate

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2022-08-01 - 2028-07-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2021-08-01 - 2024-11-30

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2023-01-01 - 2025-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2023-04-01 - 2026-01-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-09-01 - 2024-05-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2016-12-01 - 2018-06-30

Phase III

An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
  • Condition/Disease

    Treatment-resistant Depression

  • Test Drug

    ESKETAMINE

Participate Sites
8Sites

Terminated8Sites

2022-01-01 - 2024-04-09

Phase II

A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder (ADHD), Part II
  • Condition/Disease

    Attention-Deficit Hyperactivity Disorder (ADHD)

  • Test Drug

    PDC-1421 Capsule

Participate Sites
5Sites

Recruiting5Sites

1 2